Couverture de Most Innovative Companies

Most Innovative Companies

Most Innovative Companies

De : Fast Company
Écouter gratuitement

Offres de saison | 0,99 € par mois pendant les 3 premiers mois

5,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
Which companies are on the cutting edge of artificial intelligence? What’s the next major breakthrough in healthcare? How do iconic brands reinvent themselves to appeal to the next generation? Most Innovative Companies is where tech, business, and innovation convene. Join hosts Yasmin Gagne and Josh Christensen as they bring you the latest innovations transforming business and society—and highlights the companies that are reshaping industries and culture.© Fast Company | Most Innovative Companies Economie Politique et gouvernement
Épisodes
  • AI’s ROI era has arrived

    AI’s ROI era has arrived
    Oct 20 2026
    SAP’s Christian Klein on why trust and business context will separate the leaders from the rest.
    Afficher plus Afficher moins
    24 min
  • Hidden ties between the CIA and Silicon Valley

    Hidden ties between the CIA and Silicon Valley
    Oct 16 2026
    On today’s episode, MIC cohost Yasmin Gagne talks to Fast Company senior writer Rebecca Heilweil about space stocks and the commercial space boom. Then, journalist and author Sharon Weinberger tells us about her new book, “Valley of Death,” which dives deep into ties between the CIA and Silicon Valley. Check out Rebecca’s reporting here: https://www.fastcompany.com/user/rebecca-heilweil For more of the latest business and innovation news, go to fastcompany.com/news
    Afficher plus Afficher moins
    51 min
  • Curing Cancer Could Be Close

    Curing Cancer Could Be Close
    Oct 14 2026
    Stéphane Bancel has been CEO of Moderna since 2011, but it’s almost as if he's led three different companies in the past five years. First came the pandemic sprint: A biotech with no commercial products became a household name, manufacturing a billion vaccine doses in 2021 and generating roughly $18 billion in annual sales. Then, the descent. As demand for COVID shots collapsed, revenue fell roughly 90%, its stock price plunged, and Bancel had to cut thousands of jobs. Now comes another turn. Positive results from a melanoma trial with Merck have sent Moderna's stock sharply higher over the past couple of months—and offered compelling evidence for the idea Bancel was pursuing before anyone had heard of COVID-19. Moderna wasn’t built to make one vaccine. It was built around a platform: messenger RNA technology that could be adapted to fight cancer, infectious diseases, and potentially much more. The pandemic made that technology famous. An individualized cancer vaccine could reveal how much further it can go. In this conversation, Bancel explains what it takes to lead through that whiplash, what he learned from the company’s COVID detour, and what still stands between a promising clinical result and a treatment available to patients. Fast Company is the world's leading progressive business media brand, with a unique editorial focus on innovation in technology, leadership, and design. Follow us on: https://www.facebook.com/FastCompany/ https://twitter.com/FastCompany https://www.instagram.com/fastcompany/ https://www.linkedin.com/company/fast-company/
    Afficher plus Afficher moins
    45 min
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment